The cagri drug class centers on cagrilintide, an investigational amylin analog. Learn how it works, trial results, dosing, and safety facts in the US.
The cagri drug is cagrilintide, an investigational long-acting amylin analog that Novo Nordisk is developing for weight loss and type 2 diabetes. Most headlines about "cagri" actually refer to CagriSema, a once-weekly injection that pairs cagrilintide with semaglutide, the active ingredient in Ozempic and Wegovy. Cagrilintide is not FDA-approved for human use in the United States, and it is only available through clinical trials.
What Is the Cagri Drug?
Cagrilintide is a synthetic peptide designed to mimic amylin, a hormone the pancreas releases alongside insulin after meals. Amylin slows stomach emptying, signals fullness to the brain, and blunts the glucagon surges that push blood sugar up between meals.
The "cagri" nickname comes from the first four letters of cagrilintide. Like semaglutide and tirzepatide, it was built through modern peptide drug development, and it is engineered to resist enzymatic breakdown so a single subcutaneous dose lasts about a week.
Cagrilintide is an amylin analog, not a GLP-1 receptor agonist. It hits amylin and calcitonin receptors rather than GLP-1 receptors, which is why researchers see it as a different lever to pull rather than a copy of existing drugs.
Why amylin matters for appetite
Amylin is naturally co-secreted with insulin, so the body already uses it as a satiety signal. People with obesity often have altered amylin signaling, and adding a longer-acting version appears to reduce meal size and calorie intake without relying on GLP-1 pathways.
Cagri Injection, Cagri Medication, and "Cagri Supplement" Claims
Only one dosage form of cagrilintide exists in development: a once-weekly subcutaneous injection. There is no FDA-approved cagri medication, pill, or patch, and no legitimate cagri supplement.
Products sold online as "amylin" or "cagri" supplements are a different category entirely. Oral peptides are largely digested in the stomach before they reach the bloodstream, so a capsule is unlikely to deliver a drug like cagrilintide in any meaningful dose.
Buyers who type where to buy bpc-157 peptide run into the same risks that would apply here: unregulated vendors, no dosing oversight, and no guarantee the vial or capsule contains what the label claims.
CagriSema Trial Results and Dosing
CagriSema combines cagrilintide 2.4 mg with semaglutide 2.4 mg in a single weekly pen. In the REDEFINE-1 phase 3 trial, adults with obesity and without diabetes lost an average of 22.7% of their body weight over 68 weeks.
REDEFINE-2 tested the same combination in people with type 2 diabetes and reported meaningful A1c reductions alongside weight loss. Additional REDEFINE trials have looked at cardiovascular and kidney outcomes.
CagriSema would be the first amylin-based obesity drug on the US market if regulators approve it. Novo Nordisk has signaled that it plans to file for approval, but no launch date or guaranteed timeline exists.
Dosing in trials followed a slow titration schedule: a low starting dose stepped up roughly every four weeks until the target dose was reached. That approach is standard for incretin-based medications and is designed to limit nausea.
How Cagri Compares to Other Weight Loss Drugs
The table below summarizes the mechanisms and reported results that come up most often in comparisons.
| Agent | Class | US status | Reported average weight loss |
|---|---|---|---|
| Cagrilintide (cagri) | Amylin analog | Investigational | Phase 2 monotherapy data |
| CagriSema | Amylin analog + GLP-1 | Investigational | About 22.7% at 68 weeks |
| Semaglutide 2.4 mg (Wegovy) | GLP-1 | Approved | About 15% at 68 weeks |
| Tirzepatide (Zepbound) | GLP-1 + GIP | Approved | About 21% at 72 weeks |
| Retatrutide | GLP-1 + GIP + glucagon | Investigational | About 24% at 48 weeks (phase 2) |
These figures come from separate trials with different designs, populations, and analysis methods, so they are not head-to-head comparisons. A 22.7% result in one study does not automatically mean CagriSema beats a 21% result in another.
Online discussions about cagri and reta usually focus on which mechanism produces more weight loss with fewer side effects. The lilly new weight loss drug retatrutide is a triple agonist, while CagriSema pairs two hormones, so the biology is not identical.
Safety, Side Effects, and Approval Status
Gastrointestinal effects dominate the side effect profile reported in CagriSema trials. The most common complaints include nausea, vomiting, diarrhea, and constipation, and most are mild to moderate and ease as the body adjusts.
- Nausea, especially during dose increases
- Constipation or diarrhea
- Injection site reactions
- Fatigue and reduced appetite in some participants
The semaglutide component carries a boxed warning about thyroid C-cell tumors observed in rodents. That warning applies to people with a personal or family history of medullary thyroid cancer or MEN2 syndrome, who should not use semaglutide-based products.
Other serious risks associated with GLP-1 drugs include pancreatitis, gallbladder disease, and gastroparesis. CagriSema is not recommended during pregnancy, and anyone planning to conceive should stop the medication in advance under medical supervision.
Because cagrilintide is still investigational, its long-term safety profile is not fully known. No one should self-source or self-dose a peptide that has not cleared regulatory review.
Cost, Access, and Realistic Expectations
There is no retail price for cagrilintide because it is not for sale. If approved, CagriSema is expected to launch at a price comparable to other brand-name obesity drugs, which currently list above $1,000 per month before insurance, savings cards, or manufacturer discounts.
Cash-paying patients often compare published prices before filling a prescription. A walmart cash price drug list can be a useful benchmark for common generics, but investigational drugs never appear on those lists.
Weight loss from any of these medications varies widely by person, and trial results describe group averages rather than individual outcomes. Medication works best alongside nutrition support, activity, and ongoing medical follow-up.
Cagrilintide is the cagri drug, CagriSema is its most advanced formulation, and neither is available for purchase in the United States today. Anyone interested in amylin-based treatment should ask a healthcare professional about enrolling in a clinical trial rather than buying unverified products online.
Frequently Asked Questions
Is the cagri drug FDA approved?
No. Cagrilintide and CagriSema are investigational and have not received FDA approval for any indication in the United States. Novo Nordisk has signaled that it intends to file CagriSema for regulatory review, but no approval or launch date is guaranteed. Until then, the drug is only accessible through clinical trials.
What is CagriSema and how much weight loss does it cause?
CagriSema is a once-weekly injection that combines cagrilintide 2.4 mg with semaglutide 2.4 mg. In the REDEFINE-1 phase 3 trial, participants with obesity lost an average of 22.7% of their body weight after 68 weeks. Individual results vary, and the product is not yet commercially available in the US.
Can I buy cagri as a supplement or injection online?
No legitimate cagri supplement or retail cagri injection exists. Products marketed under similar names online are unapproved, unregulated, and may not contain the labeled ingredient in the stated amount. Injectable peptides should only come from licensed pharmacies under a prescription or through an approved clinical trial.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.